Award

Utility of Coronary Artery Calcification and Other Biomarkers with Statin Therapy in Multimorbid Older Adults – An Ancillary Study Nested Within a Randomized Trial

Description: Background & rationale: The benefit of statin use for primary prevention is uncertain in older adults with multimorbidity, while harms such as side effects may be more common in this population. Therefore, the 2018 AHA/ACC cholesterol guidelines mention that it may be reasonable to discontinue statins in multimorbid adults aged 75 years and older without cardiovascular disease (CVD). To better target adults who may benefit from statins in primary prevention, coronary artery calcium (CAC) measurement is rapidly increasing in clinical use and is recommended for risk re-classification in some guidelines. In addition, traditional risk prediction models perform poorly in multimorbid older adults, and addition of CAC and biomarkers may improve prediction in this population. Older patients with a high burden of subclinical atherosclerosis or elevated biomarkers associated with cardiovascular (CV) risk might benefit from continuing statins to prevent CV outcomes, but this hypothesis has not been rigorously tested in randomized clinical trials (RCTs). To address these questions, we propose to add baseline CAC and biomarkers to a planned SNF-funded randomized statin discontinuation trial with clinical endpoints among 1,800 multimorbid adults aged 70 years and older taking statins for primary prevention.Specific aims:1.To determine if the risk of a composite outcome of CV events and all-cause mortality after statin discontinuation differs among those with evidence of subclinical atherosclerosis at baseline as measured by CAC.- Hypothesis: Statin discontinuation is associated with a higher risk of CV events and mortality in participants with greater degrees of subclinical atherosclerosis, compared to those who continue.2.To determine if the risk of a composite outcome of CV events and all-cause mortality after statin discontinuation differs according to the baseline levels of previously validated blood biomarkers associated with increased risk of CV outcomes (lipoprotein(a), inflammatory markers [high-sensitivity C-reactive Protein], myocardial damage/wall strain [NT-proBNP, troponin]) and future novel biomarkers to be measured in a newly set up biobank.- Hypothesis: Statin discontinuation is associated with a greater risk of clinical CVD and mortality in participants with elevated biomarkers at baseline.3.To examine the ability of CV risk prediction models to predict short-term CVD and mortality in multimorbid adults aged 70 years and older without known CVD, and to evaluate if adding CAC and biomarkers improves risk prediction in this population.- Hypotheses: Compared to younger populations, CV risk factors are less predictive of CV events in multimorbid older adults without known CVD compared, but addition of CAC and biomarkers improves CV risk prediction.Methods: Our trial will be nested within the STREAM, an SNSF-funded investigator initiated multicenter clinical trial that will randomize 1,800 multimorbid adults aged 70 years and older with 2 or more chronic diseases but without clinically known CVD who have been taking a statin for >12 months to statin discontinuation vs. continuation. For aim 1, we will use baseline native cardiac computed tomography scan to measure CAC to identify participants with subclinical atherosclerosis. As with the overall trial, the primary outcome will be a composite endpoint of major CV events (non-fatal myocardial infarction, stroke) and all-cause death. Participants will be followed up for a minimum of 12 months (maximum 48 months, expected mean 25 months). This ancillary study will include 500 participants at several core trial sites where CAC scoring is available. To avoid bias from contamination or cross-over between trial arms, the initial results of the CT scans will be blinded to treating physicians and centrally evaluated only the end of the trial without knowledge of intervention group assignment. The trial is powered to detect an interaction between intervention group and baseline CAC score. We will first assess CAC on the continuous scale as there is currently no cut-off defined based on RCTs to initiate or discontinue statins, and in a second step we will test the effect of several CAC cut-off points. For aim 2, we will establish a biobank at baseline, and measure previously validated biomarkers on archived baseline samples. In addition, this biobank will allow measuring novel biomarkers that may be discovered in the coming years. Similar to CAC, we will first assess these biomarkers on the continuous scale, and then test cut-offs that identify participants at higher risk with statin discontinuation. For aim 3, we will evaluate several risk prediction models based on traditional CV risk factors for their ability to predict CV event risk in multimorbid older adults and will assess the incremental value of adding CAC and biomarkers to risk prediction.Expected results & impact: This efficient ancillary study nested in a large multicenter trial of statin discontinuation will determine if subclinical atherosclerosis and biomarkers of higher CV risk identify multimorbid elderly patients who might benefit from long-term statin therapy for primary prevention to prevent CV outcomes. Strengths of this proposal include: 1) novelty as there are no previous or ongoing trials of the utility of CAC scores for statin discontinuation; 2) efficient resource use with nesting within a large funded RCT; 3) unique opportunity to rigorously assess the clinical benefit of CAC score and biomarker measurements to improve identification of older adults that might benefit from statins in primary prevention; 4) potential impact independent of whether the parent STREAM trial results show or reject non-inferiority, as the proposed study allows for identification of subgroups at higher risk in the statin discontinuation group; 5) significant clinical and health systems implications as the population of older patients with multimorbidity is already large (>60% of adults aged 65 years and older) and growing.
Amount: CHF 391,900
Funding type: research
Funder scheme: Project funding
Start date: 2022-09-01
End date: 2026-08-31
Investigator: Blum, Manuel (lead)
Institutions: University of Bern, University of Berne – BE
Field: Medicine
Funded outputs count: 4
Funder award ID: 205067
OpenAlex ID: G6399788891